14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs OBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas OBIO carries 37.8/100 (SELL) at $7.00 (N/M Forward P/E, -195.4% operating margin).
Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.8/100 SELL vs. VIVS 36.8/100 SELL) and 1.14β · 86% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and OBIO (37.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $587.1M market capitalization and -195.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VIVS vs OBIO Key Questions & Quantitative Answers
As of Nov 19, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas OBIO carries 37.8/100 (SELL) at $7.00 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.8/100 SELL vs. VIVS 36.8/100 SELL) and 1.14β · 86% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and OBIO (37.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), VIVS cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.
VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus OBIO (-182.3% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.14β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.